scholarly journals A Real-World Rheumatology Registry and Research Consortium: The German RHADAR Registry (Preprint)

2021 ◽  
Author(s):  
Stefan Kleinert ◽  
Peter Bartz-Bazzanella ◽  
Cay von der Decken ◽  
Johannes Knitza ◽  
Torsten Witte ◽  
...  
Keyword(s):  
Real World ◽  
Patient Reported Outcomes ◽  
Closed Loop ◽  
Musculoskeletal Diseases ◽  
Closed Loop System ◽  
Real World Data ◽  
Patient Centered ◽  
Patient Reported ◽  
Integrated Medical Care ◽  
Research Consortium

UNSTRUCTURED Real-world data is crucial to continuously improve patients' management with rheumatic and musculoskeletal diseases (RMD). The German RHADAR registry encompasses a network of rheumatologists and researchers in Germany providing pseudonymized real-world patient data and allowing a timely and continuous improvement in RMD patients' care. The RHADAR modules allow automated anamnesis and adaptive coordination of appointments regarding individual urgency levels. Further modules focus on the collection and integration of electronic patient-reported outcomes in between consultations. The digital RHADAR modules ultimately allow a patient-centered, adaptive approach to integrated medical care starting as early as possible in the disease course. Such a closed-loop system consisting of various modules along the whole patient pathway enables comprehensive and timely patient management in an unprecedented manner.

Understanding characteristics of patients newly initiating ixekizumab: findings from the Corrona Psoriasis Registry

2020 ◽  
Author(s):  
Jashin J Wu ◽  
Ryan W Harrison ◽  
Baojin Zhu ◽  
Orin M Goldblum ◽  
William N Malatestinic ◽  
...  
Keyword(s):  
Surface Area ◽  
Body Surface Area ◽  
Body Surface ◽  
Real World ◽  
Patient Reported Outcomes ◽  
Disease Duration ◽  
Severe Disease ◽  
Work Productivity ◽  
Real World Data ◽  
Patient Reported

Background: Real-world data on patients newly initiating ixekizumab is limited. Our study describes the characteristics of patients who initiated ixekizumab and other biologics for psoriasis treatment in North American dermatological practices. Materials & methods: Characteristics of patients ascertained at registry enrollment are described via means and frequencies. Results: Compared with other biologic initiators, ixekizumab initiators had: longer disease duration (17.1 vs 15.1 years); more were considered least severe by body surface area (33 vs 26%); moderate-to-severe by IGA (56 vs 48%); were biologic-experienced (80 vs 52%); obese (54 vs 47%); and experienced greater impact in work productivity (5.3 vs 2.9%) versus other biologic initiators. Conclusion: Psoriasis patients initiating ixekizumab had more severe disease, biologic experience, and worse patient-reported outcomes than those initiating other biologics.

Real-world, Patient-Reported and Clinic Data from Individuals with Type 1 Diabetes using the MiniMed 670G Hybrid Closed Loop System

2021 ◽  
Author(s):  
Stepnanie DuBose ◽  
Colleen Bauza ◽  
Alandra Verdejo ◽  
Roy W. Beck ◽  
Richard M Bergenstal ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Real World ◽  
Closed Loop ◽  
Loop System ◽  
Closed Loop System ◽  
Patient Reported

Digitale Medizin in der Onkologie: Clinical Decision Support, Real World Data und Patient Involvement

2019 ◽  
Vol 144 (07) ◽  
pp. 430-434 ◽  
Author(s):  
Sebastian Wagner ◽  
Hubert Serve
Keyword(s):  
Decision Support ◽  
Clinical Decision Support ◽  
Real World ◽  
Patient Reported Outcomes ◽  
Patient Involvement ◽  
Clinical Decision ◽  
Real World Data ◽  
World Data ◽  
Diagnostik Und Therapie ◽  
Patient Reported

Was ist neu? Stand der Dinge In der Onkologie kam es zuletzt zu einem rasanten Wissenszuwachs. Neue Entwicklungen in Diagnostik und Therapie von Tumorerkrankungen haben die Grundlagen für individualisierte Therapiekonzepte geschaffen. Aktuell werden innovative Onkologie-spezifische IT-Lösungen entwickelt mit dem Ziel, die Heilungschancen für Patienten mit Tumorerkrankungen langfristig zu verbessern. Clinical Decision Support Die Komplexität onkologischer Therapieentscheidungen hat durch Einführung neuer Biomarker und zielgerichteter Therapeutika stark zugenommen. Erste „intelligente“ Systeme, die aktiv Therapieoptionen auf Basis von vorhandenen Daten vorschlagen, sind verfügbar, aber noch nicht weit verbreitet und unzureichend klinisch validiert. Real-World Data und Real-World Evidence Durch die zunehmende Verbreitung von elektronischen Gesundheitsakten wird eine strukturierte Sammlung und Auswertung von Daten aus der onkologischen Routineversorgung möglich. Real World Data werden eingesetzt, um die Sicherheit und Nebenwirkungen von onkologischen Medikamenten zu überwachen und können helfen, onkologische Therapieleitlinien zu entwickeln. Patient Involvement und Patient Reported Outcomes Die frühe Meldung von Symptomen und Nebenwirkungen (Patient Reported Outcomes) verspricht eine verbesserte Behandlung und eine gesteigerte Therapieadhärenz. Patient Reported Outcomes können auch im Rahmen von klinischen Studien und zur Qualitätssicherung eingesetzt werden. Erste Studien zeigen, dass eine IT-gestützte Erfassung von Patient Reported Outcomes Symptome und Überleben von Patienten mit Tumorerkrankungen positiv beeinflussen kann.

2327-PUB: Real-World Patient-Reported Outcomes (PROs) with Insulin Glargine 300 U/ml (Gla-300) in Basal Bolus-Treated People with Type 2 Diabetes (T2DM): The MAGE Study

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 2327-PUB ◽  
Author(s):  
ANN A. VERHAEGEN ◽  
ANDRÉ SCHEEN ◽  
KATHY C. ALEXANDRE ◽  
JACQUES BRUHWYLER ◽  
IDES M. COLIN
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Glargine ◽  
Real World ◽  
Patient Reported Outcomes ◽  
Patient Reported ◽  
Basal Bolus
Sign in / Sign up

Export Citation Format

Share Document